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The mitochondrion is a ubiquitous intracellular 
organelle instrumental to eukaryotic existence. It is the 
major intracellular site of oxygen consumption and 
producer of the high energy molecule adenosine 
triphosphate (ATP). Mitochondria carry out tasks 
besides energy production, including cellular 
homeostasis and signalling, iron processing, haem and 
steroid synthesis, protein and lipid biosynthesis and 
apoptosis. These organelles are extremely dynamic and 
variable, capable of responding to numerous stimuli 
(including temperature, nutrients, hormones, exercise 
and hypoxia); they initiate the production of new 
mitochondria and their selective removal.  
 
The brain, per gram, has the highest demand for glucose 
than any other tissue [1] requiring 120 – 130g glucose 
per day in adults [2]. Brain function is entirely 
dependent on glucose and oxygen from the carotid and 
vertebral circulation. Glucose oxidation followed by 
oxidative phosphorylation is accountable for the vast 
majority of ATP generated in the brain [3].  Brain energy  
 
metabolism declines with age [4]. Recent data from our 
own group [5]and others [6] have observed this decline 
to be clinically homogenous in most brain regions. This 
metabolic change is considered to be a feature of the 
ageing phenotype [4] as well as age-related neuro-
degeneration, where there is mounting evidence 
supporting the role of dysfunctional mitochondria in 
their progression [7–10].  
 
As our understanding of ageing has progressed 
mitochondrial function has come to the forefront as 
pivotal to the aged phenotype. Classical theories, 
including the mitochondrial free radical theory of 
ageing (MFRTA) [11], have led the field. According to 
the MFRTA an accumulation of oxidative damage, 
caused by mitochondrial free radicals, is the driving 
force behind ageing. However, this theory conflicts with 
growing evidence from animal models. Species 
comparison between the long lived naked mole rat and 
short lived mouse indicates little difference in the 
production of ROS between species [12] and no age-
dependent variation in antioxidant enzyme expression 
[13]. This suggests that mitochondrial ROS may act as 















Mitochondrial  dysfunction  is  evident  in  numerous  neurodegenerative  and  age‐related  disorders.  It  has  also
been linked to cellular ageing, however our current understanding of the mitochondrial changes that occur are
unclear.  Functional  studies  have  made  some  progress  reporting  reduced  respiration,  dynamic  structural
modifications  and  loss  of membrane  potential,  though  there  are  conflicts within  these  findings.  Proteomic
analyses, together with functional studies, are required in order to profile the mitochondrial changes that occur
with  age  and  can  contribute  to  unravelling  the  complexity  of  the  ageing  phenotype.  The  emergence  of
improved  protein  separation  techniques,  combined  with  mass  spectrometry  analyses  has  allowed  the
identification of age and  cell‐type  specific mitochondrial  changes  in energy metabolism, antioxidants,  fusion
and  fission  machinery,  chaperones,  membrane  proteins  and  biosynthesis  pathways.  Here,  we  identify  and
review recent data from the analyses of mitochondria from rodent brains. It is expected that knowledge gained
from  understanding  age‐related mitochondrial  changes of  the brain  should  lead  to  improved biomarkers of
normal ageing and also age‐related disease progression. 
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signalling molecules, prolonging maximum lifespan. 
Indeed this is consistent with data from mice [14], flies 
[15] and nematodes [16]. In C. elegans, despite a clear 
increase in oxidative stress due to superoxide dismutase 
(SOD) gene deletion, no change in lifespan was seen 
[17]. MFRTA also fails to fully explain the functional 
brain mitochondrial deficits that occur with age. These 
deficits include reduced respiration [18], dynamic 
changes in shape and size [19], activation of 
permeability transition pore [20] and loss of membrane 
potential [21]. Although functional studies have gone 
some way to identifying these mitochondrial changes, 
there is variability found in the direction and extent to 
which these differences occur. There is even evidence to 
suggest that oxidative phosphorylation activity may in 
fact increase with age [22–24]. There are similar 
inconsistencies which exist for the role and the activity 
of mitochondrial antioxidants [25,26], fusion and fission 
dynamics [19, 27] and other mitochondrial proteins with 
age  [28]. Profiling of mitochondrial protein expression 
in tissues from different ages can add molecular insight, 
which in conjunction with functional studies can be a 
powerful approach towards unravelling this complexity.  
In this review we look at the current state of proteomic 
technologies and focus on evaluating findings from 
mitochondrial proteomic studies of brain tissue from the 
past decade. 
 
Techniques for mitochondrial proteomic analysis 
 
Proteomics is the large scale, high-throughput 
identification of proteins within a biological unit – 
tissues, fluids or cells. First described in 1975, and still 
used to this day, the original proteomic technique is 
two-dimensional gel electrophoresis (2DE) [29]. This 
involves the separation of proteins initially by their 
isoelectric point and secondly by their molecular 
weight. Proteins are resolved within the biological 
sample into spots on a stained gel which each represent 
one or a small number of proteins. 2DE has well 
recognised limitations, reviewed by Rabilloud and 
Lelong (2011) [30]. 2DE analysis of membrane proteins 
is not suitable due to isoelectric precipitation [31]. 
Further, 2DE presents a limited scope of analysis of 
whole cell extracts [30]. However, despite the 
limitations it is a very economical, robust and 
reproducible method which has stood the test of time. It 
still has some utility in profiling individual cellular 
fractions, including mitochondria, where the sample 
complexity is closer to the resolving power of 2DE [7, 
32].   
 
The fluorescent younger sibling to 2DE is two-
dimensional difference in-gel electrophoresis (2D-
DIGE), reviewed by Diez et al (2010) [33]. 2D-DIGE 
involves the pre-labelling of two or more protein 
samples, before they are run on the same gel. They are 
labelled at cysteines or lysines with cyanine dye 
(CyDye) fluorophores (Cy2, Cy3 and Cy5). 2D-DIGE 
facilitates ease of comparison between two or more 
proteomes, reducing the number of gels, cost and time 
required. It includes the use of an internal pooled 
standard which is particularly useful for normalisation 
of identified spots without the need for classical pair-
wise analysis. However, similar to classical 2DE it 
shares drawbacks in keeping hydrophobic and 
membrane proteins from precipitating [33]. There is 
also some difficulty in resolving very high or very low 
molecular weight or extreme isoelectric point proteins.  
One more gel based technique, blue native gel 
electrophoresis (BN-PAGE) is used for the isolation of 
membrane bound protein complexes BN- PAGE has 
been used to separate and recover the oxidative 
phosphorylation machinery of the inner mitochondrial 
membrane [34]. Mass spectrometry (MS) (reviewed by 
Cunningham et al, 2012) [35] is the central technology 
for the identification and characterisation of proteins 
from spots identified with 2DE/2D-DIGE/BN-PAGE. 
Briefly, protein spots of interest are excised, trypsin 
digested and masses are measured on MS-instruments 
to produce a peptide mass fingerprint, which is 
compared against an in silico database.  
 
Despite the utility of 2DE/MS, 2D-DIGE/MS and BN-
PAGE, and their use within mitochondrial proteomic 
ageing research [36–38,7], new methods have been 
developed with further advantages [39]. Technological 
advances in gel-free liquid chromatography have 
stepped up in delivering these. Proteomic analyses, 
including research within mitochondrial ageing 
dynamics, more frequently employ liquid chromato-
graphy coupled with mass spectrometry (LC/MS-MS) 
[40]. Liquid chromatography comes in a variety of 
modes: ion-exchange, reverse phase, affinity and size 
exclusion chromatography (reviewed by Pitt, 2009) 
[41]. Each modality has its own set of positives and 
negatives to its use, however most proteomic 
separations are carried out in reverse phase - LC mode 
due to its compatibility with MS. LC/MS is a viable 
replacement for older proteomic technologies, as it 
provides superior specificity and sensitivity, although 
highly trained personnel are essential and start-up costs 
are large [42].  
 
In the proteomic quantification of mammalian tissues in 
vitro and in vivo stable isotopic labelling (reviewed by 
Gevaert et al, 2008) [43] and label-free techniques are 
used (reviewed by Wong and Cagney, 2010) [44]. In 
vivo methodologies include stable isotope labelling by 
amino acids in cell culture and also in mammals 
(SILAC), and in vitro options include isotope-coded 
affinity tag (ITRAQ). These methods boast greatly 
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increased sensitivity compared to traditional 2D-PAGE 
techniques, due to chromatographic separation [45]. 
However, as with all techniques stable isotopic labelling 
suffers some disadvantages in methodology. A major 
drawback of SILAC is its inapplicability to whole tissue 
protein analysis [45]. ITRAQ relies on the differential 
tagging of cysteine residues in proteins. However, this 
is a drawback due to it missing approximately 5-10% of 
all proteins where this amino acid is not present [45]. 
Further, isotope labelling requires avidin affinity and 
ion-exchange chromatography to be carried out, causing 
losses in low abundance peptides [46]. More recently, 
label free methods, including sequential window 
acquisition of all theoretical mass spectra (SWATH), 
have been developed to overcome the limitations of 
label-based quantification and its complexity of sample 
preparation [47]. SWATH-MS combines data 
independent acquisition with a targeted data extraction 
method. It has been demonstrated to have an equivalent 
standard of quantification accuracy to that of label-
based methodologies [48], whilst being able to detect 
and quantify a significantly larger proportion of the 
proteome [49] and maintain reproducibility and 
consistency [50]. SWATH-MS has not yet seen use 
within the field of mitochondrial proteomics, however 
SWATH-MS is clearly a current leader in the field of 
proteomic techniques. 
 
Proteomic methods have matured over the past few 
decades, however the continued progress toward 
increased resolution, accuracy and reproducibility will 
allow inclusion of lower abundance proteins and those 
that are less well resolved with current techniques. New 
methods such as SWATH-MS [47], reaction 
monitoring/multiple reaction monitoring [51] and 
SELDI-TOF-MS  (surface  enhanced   laser  desorption/ 
ionisation of flight mass spectrometry) [52] are 
currently being validated and should be expected to 
replace older 2DE/2D-DIGE methods. Indeed within 
mitochondrial ageing research some of these more 
cutting edge technologies, including SILAC, have 
already been demonstrated [22,53,54]. 
 
What does proteomics tell us about mitochondrial 
brain ageing?  
 
With evidence pointing toward a pivotal role of 
mitochondria in neurodegenerative disease and the aged 
phenotype, an understanding of the changes to the 
proteome is warranted. Searching within the NCBI 
Pubmed database using the terms ‘proteomics and 
mitochondria and aging or ageing’ supplied a total of 
six relevant proteomic studies to this review since 2006. 
Further, a number of reviews have been published in the 
past 5 years within the mitochondrial proteomic 
paradigms of neurodegenerative disease [55] and 
muscle ageing [56], illustrating the current popular 
interest that exists for this subject. For this review we 
focus upon the mitochondrial proteomic studies within 
brain tissue in mice [22,38,7,53,54] and rats [37], from 
the last 10 years. 
 
The six mitochondrial proteomic studies found relevant 
to this review (summarised in Table 1) used a variety of 
experimental approaches. Studies used either 2DE+MS 
(3 out of 6 papers) [37,38,7], or non-gel based SILAC + 
HPLC/MS-MS (3 out of 6 papers) [22,53,54].  All mice 
used were CB57L/6 or CB57L/6J, whilst rats were 
F344/DuCrj. An inconsistency exists between the 
reviewed studies here in respect of the age of tissues 
profiled. Study designs comprised varying start and end 
ages, outlined in Table 1. Briefly, age ranges included 
young to middle aged (5 out of 6 papers), middle to old 
aged (3 out of 6 papers) and young to old aged (4 out of 
6 papers). Although this differential study design may 
influence interpretation of the proteomic differences, it 
has proved useful in order to highlight the variation of 
mitochondrial protein expression that has been 
measured across the lifespan. We have chosen to look 
more broadly at brain mitochondrial proteomic 
alterations, including whole brain, rat left brain, 
individual cell types (neural progenitor cells) and cell 
compartments (synapse) within this review. This 
overview may lead to a more complete understanding of 
the complex differences of how mitochondrial ageing 




Mitochondrial oxidative phosphorylation (OXPHOS) is 
a process of electron transfer through complexes I, II, 
III and IV situated on the inner mitochondrial 
membrane (IMM). Electrons are released into the inter-
membrane space and re-enter through the F0 subunit of 
complex V (ATP synthase) and are utilised to form 
ATP by F1-ATP synthase. Electron transfer proteins 
have been measured as decreased in ageing brain [57], 
with most prominent changes seen in complexes I, III, 
IV and V [58-60]. Taken together, proteomic studies 
have generally found similar reductions in OXPHOS 
protein expression within whole brain tissue. A decrease 
in expression of proteins associated with complex I 
(NADH-ubiquinone oxidoreductase 1 alpha subcomplex 
5 and NADH-ubiquinone oxidoreductase 13kDa-a 
subunit) from 12 -24 [54] months old and over the 
lifespan at 5 – 24 [38] months old is seen. Proteomic 
profiling of complex II, similar to functional study 
reports, does not show significant change with age in all 
but one whole brain profile, with an increase in 
succinate dehydrogenase flavoprotein subunit from 5 – 
12 months old and a corresponding decrease from 12 – 
24 months old [54]. Interestingly, in contrast to 
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functional studies, within whole brain and isolated brain 
regions the expression of proteins associated with 
complex III show no change in all but one proteomic 
profile, in which an increase in cytochrome b-c1 
complex subunit Rieske is increased from 5 – 12 
months old and decreased from 12 – 24 months old 
[54]. In mouse whole brain complexes IV and V show a 

















































and a decrease in expression from 12 – 24 months old 
[38] with multiple subunits of complex IV (cytochrome 
c oxidase subunit Vb, cytochrome c oxidase subunit Va 
preprotein) and complex V (ATP synthase 
mitochondrial F0 complex subunit F, ATP synthase 
subunit alpha; subunit beta; subunit delta) being 
affected. In rat brain however, a decrease in complex IV 

























































2006 Mao et al., Whole brain C57BL/6 mice 5 - 24 months 2DE/MS Energy metabolism and HSP changes. Decreased 
protein expression of complexes I and IV and an 
increased expression of complex V of the electron 
transport chain with age. HSP10 decreased 
expression with age. 
2007 Groebe at al. Left brain F344/DuCrj 
rats 
5 - 17, 17 - 
31, 5 - 31 
months 
2DE/MS Energy metabolism, HSP and haemoglobin subunit 
changes. Decreased protein expression of complex 
V with age. Complex IV decreased expression at 17 
- 31 and 5 - 31 months. 1 TCA cycle protein 
upregulated at 5 - 17 months and downregulation of 
two proteins at 17-31 and 5 - 31 months. HSP70 
decreased expression from 5 - 31 months. 
Haemoglobin subunit alpha upregulated at 5 - 17 
months and downregulated at 17 - 31 months. 
2011 Stoll et al. Neural 
Progenitor 
Cells 
C57BL/6 mice 3 - 18 months SILAC 
(labelled) 
LC/MS-MS 
Energy metabolism, HSP, VDAC and protein/lipid 
biosynthesis changes. Decrease in complex V 
protein expression. 2 TCA cycle proteins 
upregulated and 3 downregulated. 1 VDAC protein 
downregulated. 1 HSP downregulated and 2 
upregulated with age. 2 protein biosynthesis proteins 
upregulated. 2 lipid biosynthesis proteins 
upregulated and 1 downregulated. 
2014 Stauch et al. Synapses C57BL/6 mice 5 - 12, 12 - 





Energy metabolism, antioxidant, fusion and fission 
protein expression changes. Decreased protein 
expression of complexes I, III, IV, V, 3 antioxidant 
proteins and 3 fusion related proteins; increased 
expression of 1 fission related protein at 5 - 12 
months. Opposite expression profile from 12 - 24 
months. Increased protein expression of complex II 
from 5 - 24 months.  
2015 Stauch et al. Whole brain C57BL/6 mice 5 - 12, 12 - 
24, 5 - 24 
months 
LC/MS-MS Energy metabolism, antioxidant, protein and lipid 
biosynthesis, haemoglobin subunit, fusion and 
fission protein expression changes. All ETC 
complexes, 9 TCA cycle proteins, 7 lipid 
biosynthesis proteins, 5 protein biosynthesis 
proteins, 2 antioxidant proteins and 1 fusion related 
protein  increased from 5 - 12 months. 2 antioxidant 
proteins decreased from 5 -12 months. Opposite 
profile from 12 - 24 months, plus 2 fission related 
proteins downregulated. Few changes from 5 - 24 
months. 1 VDAC protein increased from 5 - 12 
months, subsequent decrease from 12 - 24 months. 1 
HSP protein upregulated and 1 downregulated from 
5 - 12 months. 2 HSPs downregulated from 12 - 24 
months. Haemoglobin subunit beta downregulated 
from 5 - 12 and 5 - 24 months. 
2016 Pollard et al. Whole brain C57BL/6 mice 4-11 and 78 
weeks 
2DE/MS Energy metabolism and Carbonic Anhydrase II 
expression changes. Increased expression of 
complex I. Deacreased expression of 1 TCA cycle 
protein. Increased expression of carbonic anhydrase 
II. 
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old, however downregulation of complex V is seen at 
all time points (5 – 17, 17 - 31 and 5 – 31 months old) 
[37]. It is clear there is an overall reduction in OXPHOS 
protein expression in advanced age, with major 
expression changes in complexes I, IV and V. These 
results can be interpreted a number of ways. It may be 
that there is a reduction in overall energy metabolism or 
an increased propensity for glycolytic energy 
production. As the central producer of ROS this 
modulation of expression may be in response to the 
increased free radical induced stress, either as a 
consequence of ROS signalling or oxidative damage to 
the protein complexes. 
 
Looking at the RNA level, previous mitochondrial gene 
expression analyses have found similarities to the 
pattern revealed within the proteome [61]. A similar 
‘time-course’ to mitochondrial protein expression, with 
increased gene expression of complexes I, III, IV and V 
in 12 and 18 month old mice compared to 2 months old 
and a decreased expression in 24 month olds. A 
mitochondrial proteomic study looking at mouse brain 
over the lifespan (5 – 24 months old) found limited 
changes in OXPHOS protein expression, however from 
young to middle aged and middle to old aged showed 
distinct expression changes [54]. In whole brain from 4-
11 week and 78 week old mice an increase in 
expression of a single subunit of complex I (NADH 
dehydrogenase flavoprotein 2) was seen [7], whilst only 
a decrease in protein expression of complex V was 
apparent in neural progenitor cells (NPCs) taken from 3 
and 18 month old mice [53]. Taken together, these data 
suggest that the proteomics of mitochondrial ageing are 
acutely sensitive to stage of life and a simple snapshot 
in time is not sufficient to deduce the role that 
differential mitochondrial proteomics can have over the 
lifespan.  
 
Interestingly, synaptic mitochondria showed a clearly 
contrasting pattern of OXPHOS protein expression 
changes when compared with whole brain [22]. The 
synaptic cell region, where neuronal communication 
occurs, is reliant on an efficient supply of ATP for 
vesicle mobilisation and maintenance of membrane 
potential [62]. In synaptic mitochondria a decrease in 
protein expression of complexes I, III, IV and V at 5 – 
12 months old was followed by an increase in protein 
expression of complexes I, III, IV and V at 12 – 24 
months old. Similar to a whole brain lifespan proteomic 
comparison [31], within the synapse little difference 
was found in protein expression levels of any complex 
at 5 – 24 months old, with only an increase in 
expression of complex II seen. The brain mitochondria 
from whole brain and individual regions of neurones 
can be expected to be more heterogeneous due to the 
number of cell types that would be included. This look 
at an individual neuronal cell compartment, the synapse, 
highlights the differential mitochondrial protein 
expression levels that may occur within different cell 
types and regions in order to compensate for specific 




The tricarboxylic acid (TCA) cycle takes place within 
the mitochondrial matrix and is tasked with the 
conversion of pyruvate, generated from glycolysis, into 
acetyl-CoA. Acetyl-CoA is further converted into CO2, 
resulting in the production of reducing equivalents such 
as NADH for the electron transport chain, and the 
eventual production of ATP. Few studies have looked at 
TCA cycle proteins specifically with age. In the flight 
muscle of drosophila a reduction in aconitase activity is 
seen with advancing age [64]. Aged mouse kidney 
mitochondria also show decreased expression of 
aconitase and α-ketoglutarate dehydrogenase, and 
conversely an increased expression of isocitrate 
dehydrogenase [65]. Within Parkinson’s disease there is 
reduced activity of the α-ketoglutarate dehydrogenase 
complex [66], which may pre-dispose affected regions 
to damage. Dysregulation of the cycle at any step may 
lead to inefficiencies in OXPHOS and thereby disrupt 
mitochondrial bioenergetics.  
 
Two of the studies fail to make any mention of TCA 
cycle proteins, either focussing specifically on other 
proteins or finding no changes (2 out of 6 papers) 
[22,38]. Otherwise, a common theme in 5 – 12 month 
old mouse whole brain[54] and 5 – 17 month old rat 
brain [37] was an increase in expression of TCA cycle 
proteins (isocitrate dehydrogenase, isocitrate 
dehydrogenase 3, oxoglutarate dehydrogenase, malate 
dehydrogenase, fumarate hydratase, pyruvate dehydro-
genase E1 alpha 1, aconitate hydratase, dihydrolipoyl 
dehydrogenase, succinyl-CoA ligase). A subsequent 
decrease in the same proteins from 12 – 24 months old 
in mice [54] and 17 – 31 months old in rats [37] 
followed. Similarly to OXPHOS protein changes over 
the entire lifespan, fewer changes were seen. From 5 – 
24 months old, one mouse study failed to find any 
changes in TCA cycle protein expression [54], whilst a 
whole lifespan study in rats [37] showed decreases in 
two TCA cycle proteins only (isocitrate dehydrogenase 
3 and malate dehydrogenase). Looking at NPCs taken 
from 3 and 18 month old mice and 4-11 and 78 week 
old mice whole brain some clue is gained as to the 
progression of changes in mitochondrial protein 
expression with increasing age, and further evidence for 
the heterogeneity of brain tissue. In whole brain only 
one protein has been found to show expression changes; 
pyruvate dehydrogenase is decreased [7], whilst in 
NPCs three TCA cycle proteins are downregulated at 18 
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months old (oxoglutarate dehydrogenase, citrate 
synthase and fumarate hydratase), while two are 
upregulated (malate dehydrogenase and aconitate 
hydratase) [53]. These differential findings at various 
ages and in whole brain, neuronal compartments and 
cell types highlights the necessity for a comprehensive 
understanding of mitochondrial proteomic dynamics 
over the lifespan. 
 
To summarise, mitochondrial proteomics reveal a 
decreased expression of both TCA cycle and OXPHOS 
proteins with advanced age. A decrease in the 
production of reducing equivalents from the TCA cycle 
attenuates the feed into the electron transport chain, for 
the synthesis of ATP. Decreased TCA cycle protein 
expression may therefore indirectly reduce age related 




Evidence for the changing regulation of mitochondrial 
antioxidants is mixed. It is seen that the production of 
mitochondrial superoxide does increase with age and 
increased oxidative damage is seen in the elderly [67]. 
In muscle, mitochondrial antioxidant activity is 
increased to compensate for this [68], however there are 
also studies that suggest little change or  decrease in 
protein and mRNA levels of these mitochondrial 
enzymes occurs with age [69]. Looking at the naked 
mole rat, the longest lived rodent species with a 
maximum lifespan of 25-30 years, mitochondrial ROS 
production is very similar to the short lived mouse, with 
a maximum lifespan of 2-3 years [12]. However, there 
are no age-related variations in antioxidant enzyme 
expression [13], whereas ROS damage continues to 
increase with age [70]. Although mitochondrial 
antioxidants are critical to an organisms survival, as of 
yet these data show no strong evidence for the necessity 
of modulation of mitochondrial antioxidants with 
advancing age.  
 
Four of the mitochondrial proteomic studies found no 
changes in antioxidant levels with age (4 out of 6 
papers) [37,38,53,7] - those that do mirror the 
uncertainty in the literature. In mouse whole brain a mix 
of up and downregulated antioxidants is seen at 5 – 12 
months and 12 – 24 months old [54]. Superoxide 
dismutase 2 (SOD2) and peroxiredoxin-3 (PRDX3) are 
upregulated and glutathione S-transferase 1 and gamma-
glutamyltransferase 7 (GGT7) are downregulated at 5 – 
12 months old. At 12 – 24 months old SOD2 is down-
regulated and PRDX2 and GGT7 are upregulated. 
Comparatively, isolated mitochondrial synapses show a 
clear pattern of downregulated antioxidant proteins at 5 
– 12 months old and upregulation at 12 – 24 months old 
(catalase, PRDX5, SOD2) [22]. Both synaptic and 
whole brain isolated mitochondria from 5 – 24 months 
old show no differences in antioxidant producing 
protein levels over the lifespan [22,54]. Too few data 
currently exist from proteomic profiling to do anything 
but add to the confusion surrounding the understanding 
of the role antioxidants play in the ageing phenotype. 
 
Much effort has been directed towards understanding 
antioxidants and their role in combating increased 
oxidative damage with progressive age, yet so far little 
evidence exists from functional studies to solidify their 
importance. Proteomic studies of the mitochondria with 
age have also failed to clarify their importance. 
Accumulating evidence from long-lived species [12,13], 
little evidence supporting a role in lifespan 
enhancement [17,71–74] and evidence supporting the 
role of free radicals as signalling molecules beneficial to 
adaptive ageing[75,76] should move us past long held 
perceptions. Antioxidants may not be as important as 
we previously thought them to be to lifespan extension 
or to ageing. Much more effort should be placed into 
understanding the role antioxidants play in the general 
maintenance of mitochondrial health. 
 
Heat shock proteins 
 
The first line of cellular defence are proteases and 
chaperones, including heat shock proteins (HSPs). HSPs 
are just one family of proteins tasked with surveillance 
of cellular faults to ensure repair, degradation or 
removal. HSPs have many functions within the 
mitochondria, including the maturation of mitochondrial 
protein imports from the cytosol [77]. Most proteins are 
imported into the mitochondria in a pre-protein, 
unfolded state. Final destination transport and folding 
are in part mediated by HSPs. HSP70 and 90 deliver 
pre-proteins to the outer mitochondrial membrane 
receptor subunits of the Translocase of the Outer 
Membrane (TOM) complex for onwards import into the 
matrix [77,78]. The mitochondrial compartments each 
contain their own chaperone pool. Within the matrix the 
main chaperone is mitochondrial HSP70 (mtHSP70). 
The role of mtHSP70 is not fully understood, however 
evidence suggests it maintains the inward movement of 
pre-proteins from the cytosol into the mitochondria 
through conformational change of mtHSP70 together 
with ATP hydrolysis [79,80]. MtHSP70 is involved in 
assisting protein folding in the matrix [81,82] and it has 
been shown that it may be a pro-apoptotic factor [83]. 
After release of the substrate by mtHSP70, 
HSP60/HSP10 chaperonin system interacts with the 
incompletely folded protein [84,85]. The HSP60/HSP10 
complex is critical for proper protein folding as loss of 
function leads to an accumulation of protein aggregates 
[85]. Similarly to mtHSP70, there is some evidence to 
suggest that HSP60/HSP10 are pro-apoptotic [86]. 
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HSPs are clearly extremely important proteins for 
maintenance of mitochondria. Any modulation of their 
expression may therefore have a critical impact upon 
mitochondrial function. 
 
Increased protein misfolding is a hallmark of ageing and 
neurodegenerative disease where mitochondrial HSPs 
have been found to change expression. Import 
efficiency of mitochondrial proteins involved in repair 
of oxidatively damaged mtDNA has been seen to 
decrease with age [87,88]. A histological hallmark of 
certain neurodegenerative diseases, including 
Parkinson’s disease and Lewy body dementia is the 
accumulation of fibrillary aggregates known as Lewy 
bodies (LBs) [89]. HSP90 and HSP60 are found 
extensively as components of LBs [90–93]. The 
accumulation of these aggregates is primarily due to 
protein misfolding [94]. In Parkinson’s disease LBs are 
found within the cytoplasm of dopaminergic neurones 
of the substantia nigra [94]. A loss of dopaminergic 
neurones of the substantia nigra and thus its 
dopaminergic projections to the striatum mark the 
pathology of Parkinson’s disease [94]. A recent 
proteomic study in mouse substantia nigra and striatum 
over the lifespan showed region specific differences in 
HSP expression [95]. The group found a loss of HSP60 
in the substantia nigra only. No change in expression of 
HSP90 was found in either the striatum or substantia 
nigra. A decrease in expression of HSP60 within the 
substantia nigra with age could promote an environment 
more suitable to the accumulation of LBs in Parkinson’s 
disease. Ageing has also been seen to cause a reduction 
in HSP90 expression in response to thermal stress in 
mesenchymal stem cells [96], liver cells [97] and 
lymphocytes [98]. Further, aged animal tissues and 
elderly human blood have shown a reduced production 
of HSP90 following thermal stress [99]. The tissue 
heterogeneity of mitochondrial HSP expression with 
age has also been addressed recently. A tissue specific 
change in mtHSP70 was shown, with increased 
expression in 24 month old rat kidney and lungs, 
decreased expression from 18 – 24 months old in testis 
and no change in liver with ageing [100]. 
 
Four proteomic studies found changes to the expression 
of HSPs with age [37,38,53,54]. In mouse brain, HSP60 
was found to increase its expression from 5 – 12 months 
old and subsequently decrease at 12 – 24months 
old[54]. The partner to HSP60, HSP10, was also found 
to decrease with advanced age in two mouse brain 
models, from 12 – 24 months [54] and 5 – 24 months 
old[38]. mtHSP70 was found to decrease its expression 
in two mitochondrial proteomic profiles, in NPCs from 
3 – 18 months old [53] and in rat brain from 17 – 31 
months old [37]. Transporter of pre-proteins from the 
cytosol to the mitochondrion, HSP90, was also profiled 
by two papers [53,54]. In NPCs there was an 
upregulation in HSP90ab1 and HSP90b1 from 3 – 18 
months old [53], whereas in mouse brain from 5 – 12 
months old it was seen to decrease [54].  
 
What is clear from functional studies is that HSPs 
remain an unknown quantity in regards to expression 
changes with age, and mitochondrial HSPs even more 
so. HSPs are involved in protein quality control, 
trafficking of proteins into the mitochondria and correct 
folding of incoming proteins. As an increased 
aggregation of misfolded proteins is a known 
occurrence with age it would be logical to assume HSPs 
would be upregulated. Indeed, within functional studies 
there is evidence to suggest tissue specific increases in 
mitochondrial HSPs with ageing [100]. However, 
proteomic data do not indicate that this is the case 
within brain tissue in advanced age. Brain region 
specific differences could be a reason for this, or there 
may have been a rise in HSP levels with progressive 
ageing, however HSP defences may eventually fail in 
advanced age due to overwhelming proteotoxic stress. 
Recently, mitochondrial HSPs have been proposed to 
also be pro-apoptotic factors [83,86]. There is also a 
decrease in global apoptosis with progressive age [101]. 
Therefore, this decrease in brain mitochondrial HSPs 
could be considered to play a role, as a cause or a 
consequence, of reduced apoptosis. Both functional and 
proteomic studies looking into this are warranted. The 
complexity and limited current knowledge of 
mitochondrial HSP expression is apparent. It is likely 
the degree of expression of these proteins is varied with 
oxidative stress, tissue, region and cell type, disease 
progression and likely a multitude of other variables. 
However, with key roles in mitochondrial maintenance 
and protein folding and evidence indicating expression 
changes with age and within regions involved in 
neurodegenerative disorders, they are a family of 
proteins of immense therapeutic potential. 
 
Fusion and fission 
 
Fusion and fission are counters of each other. Fusion and 
fission dynamics are strongly influenced by energy and 
supply balance. Nutrient-rich environments are 
associated with a fragmented mitochondrial network, 
whereas fasting is associated with mitochondrial 
elongation [102–104]. The morphology of mitochondria 
have a critical impact on ATP production, with elongated 
mitochondria being essential to maintain ATP production 
and cellular survival, whereas mitochondrial 
fragmentation decreases ATP production and increases 
mitochondrial uncoupling and nutrient storage [102,103]. 
Mitochondrial fission may also cause mitochondrial 
depolarisation leading to whole organelle turnover, 
known as mitochondrial autophagy or mitophagy [105]. 
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Alterations of mitochondrial dynamics can cause 
mitochondrial dysfunction and cellular senescence 
[106].  In Alzheimer’s disease there is an increase in 
mitochondrial fragmentation coupled with increased 
autophagy [107–109]. Parkinson’s disease patients 
show an increase in mitochondrial fragmentation due to 
increased fission protein Dynamin-1-like protein 
(DRP1) and cleavage of fusion protein Optic atrophy 1 
(OPA1) [110]. In Purkinje cell degeneration (pcd) mice, 
a model of neurodegenerative disease, degeneration of 
Purkinje cell neurones is thought to be caused by over-
activation of the macroautophagy pathway and 
mitophagy, indicating that an altered autophagy 
pathway may be common within neurodegenerative 
diseases [111]. Ageing seems to accompany a shift 
toward more fusion events, resulting in elongated, 
enlarged mitochondria[28]. It has recently been shown 
that a loss of DRP1 is found during senescence in aged 
mice endothelial cells, causing an upregulation of ROS 
[112]. Recent studies in mouse hypothalamic neurones 
have implicated a lack of Mitofusins (Mfn1 and Mfn2) 
with whole-body energy homeostasis regulation [113–
115]. Mfn2 deficiency was found to reduce endoplasmic 
reticulum (ER) communication and prevent changes in 
mitochondrial dynamics, causing insulin resistance and 
hypothalamic leptin resistance; thereby leading to obesity 
[116,117]. Tight contact between the ER and 
mitochondria is pivotal for mitochondrial and ER health, 
as the ER provides important resources, including 
calcium ions and mitochondrial lipids. ER stress induced 
by Mfn2 deficiency is known to promote the pro-
inflammatory transcription factor NF-kB [118]. NF-kB 
family of transcription factors is capable of stimulation 
by a variety of inflammatory, oxidative and genotoxic 
stresses; therefore, it is very likely to have involvement 
within ageing [119]. In the hypothalamus of mice, 
inhibition of NF-kB signalling in microglia was capable 
of extending lifespan [120]. This suggests that increased 
Mfn2, and thus increased fusion, may provide benefits to 
ageing and improved lifespan through a reduction of NF-
kB. Age-related decrease in mitochondrial tethering to 
the ER, including ER stress-induced reduction in insulin 
signalling, may be an important age-associated regulatory 
change. Although correlation exists between 
mitochondrial elongation and ageing, the exact 
contribution is still debated. It has been shown that 
prolonged elongation of mitochondria results in greater 
intracellular ROS production and lower mitochondrial 
respiration rate [121]. On the other hand, in response to 
cellular stress, mitochondrial fusion allows mito-chondria 
to possess more cristae, maintain ATP production, 
prevent mitochondrial membrane depolarisation, inhibit 
cytochrome C release and to escape from mitophagy and 
apoptosis [122]. Therefore, mitochondrial fusion may be 
important in times of cellular stress to allow 
mitochondria to regain cellular functionality.  
Only two mitochondrial proteomic studies have found 
alterations in fusion and fission mechanics regulation 
[22,54]. Both are in agreement that a reduction in 
fission is seen from 12 – 24 months old (DRP1 and 
mitochondrial fission factor) in mice [22,54]. An 
increase in fission from 5 – 12 months old is also seen 
within synaptic mitochondria only [22]. Fusion 
mechanics are less well defined with age from the 
proteomic studies that have characterised them. Within 
a whole brain model, from 5-12 months old fusion 
increases (MFN1), whilst from 12 – 24 months old it is 
seen to downregulate (OPA3, MFN1) [54]. Within 
synaptic mitochondria however, the opposite was 
found: fusion proteins are downregulated from 5 – 12 
months old (MFN1, MFN2, OPA1) and upregulated 
from 12 – 24 months old (MFN1, MFN2, OPA1) [22]. 
Due to the high reliance of the synapse on an efficient 
supply of ATP, the upregulation of fusion proteins with 
advancing age may be a compensatory mechanism to 
rescue cellular functionality through maintaining ATP 
production, increase number of cristae, prevent 
mitochondrial membrane depolarisation, inhibit 





Voltage dependent anion channels (VDAC) are the 
most abundant protein in the outer mitochondrial 
membrane (OMM). They are an important component 
of the mitochondrial permeability transition pore, 
facilitating the trafficking of <5kDa metabolites through 
the OMM and are involved in ER – mitochondria 
crosstalk [123]. It has been shown that superoxide 
produced by complexes I [124] and III  [125] are 
released from the mitochondria through VDACs in 
times of pathological stress or decreased mitochondrial 
antioxidant levels. VDAC is thought to participate in 
the intrinsic apoptosis pathway. The intrinsic apoptosis 
pathway involves the permeablisation of the OMM, as a 
mitochondrial transition pore. VDAC is involved in 
cytochrome C release, although the exact mechanism is 
under dispute [126]. VDACs come into direct contact 
with both pro- and anti-apoptotic factors [127,128]. The 
complexes formed through VDAC/apoptotic factor 
binding are poorly understood although their structures 
have been predicted [129]. The precise role for VDAC 
within the apoptotic cascade is currently unknown.  
 
The dysregulation of mitochondria-mediated apoptosis 
has a role in ageing [130] and neurodegenerative 
disease [131–134]. However, the direction of apoptotic 
protein expression, enhancement [135] or suppression 
[101], is questioned. On the one hand too little 
apoptosis can lead to accumulation of dysfunctional 
cells, while too much can cause degeneration of tissues. 
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Recent evidence in humans has pointed toward a 
decrease in apoptosis with age, including a decrease in 
pro-apoptotic proteins and apoptotic markers and an 
increase in anti-apoptotic proteins [101]. As VDAC is a 
component of apoptosis through its interactions with 
apoptotic proteins and is involved in cytochrome C 
release its expression in ageing and neurodegeneration 
may be expected to change. Indeed, in Alzheimer’s 
disease there is an increase of VDAC2 in the temporal 
cortex and a decrease of VDAC1 in frontal cortex [136]. 
In familial ALS, post-translational modifications of 
VDAC2 have been reported [137]. Further, in the 
hippocampus of an epileptic model mouse, a 3-fold 
increase in VDAC1 and 4-fold decrease in VDAC2 was 
seen [138]. A study on VDAC expression with age 
within a human ageing model, human umbilical vein 
endothelial cells (HUVEC), and aged Drosophila found 
a change in expression and post-translational 
modifications [139]. In Drosophila a decrease in 
expression was found in 3 isoforms of VDAC1 and an 
increase in expression was found in one. In HUVEC an 
increase in expression was found in VDAC2. Currently 
two mitochondrial proteomic papers have profiled 
VDAC proteins with age [53,54]. Here there is 
agreement that the expression of VDAC1 decreases in 
advanced age [53,54]. No other VDAC family member 
showed expression change with age. There was also 
found to be an increase in VDAC1 from 5 – 12 months 
old [54], once again hinting at a time-course to 
mitochondrial protein expression within the VDAC 
family of proteins as well. As VDAC is suggested to be 
involved in the apoptotic cascade through multiple 
mechanisms, including cytochrome C release and 
interaction with apoptotic proteins, the decrease in 
VDAC protein expression shown from these proteomic 
analysis with advanced age is in agreement with 




Haemoglobin (Hb) is well known as a transporter of 
oxygen, carbon dioxide and nitric oxide, however it is 
also involved in regulation of gene expression, nitric 
oxide signalling and terminal oxidase activity [140]. It 
is a heterotrimeric protein comprised of two alpha (Hba) 
and two beta (Hbb) subunits. Within each subunit of Hb 
is a haem group with an Fe2+ core which allows Hb to 
bind gaseous molecules. A recent finding is the 
localisation of Hba and Hbb to the mitochondrial inner 
membrane [32]. It has been postulated that a close 
proximity to the oxidative phosphorylation machinery 
may be important for maintenance and support in times 
of oxidative stress.  
 
Hba and Hbb are expressed within neurones and 
localisation to the mitochondria is known to occur 
within the substantia nigra and frontal lobe [32]. Hba 
and Hbb mRNA are strongly downregulated within the 
brain with age [141] and within animal models of 
neurodegeneration[142]. Post-mortem PD patient 
substantia nigra [32,143] and medulla oblongata [143] 
have reduced Hba and Hbb. It has been shown that 
mitochondrial Hba and Hbb are decreased in 2 – 18 
month old control and neurodegenerative model mice 
[32]. Two proteomic papers have so far described the 
protein expression of Hba and Hbb within ageing brain 
mitochondria [37,54]. Similarly to functional studies 
within the brain Hba and Hbb have been found to 
decrease with ageing. In mice Hbb protein expression 
decreased from 5 – 24 months old [54] and in rats Hba 
expression decreased from 17 – 31 months old [37]. 
From young to middle aged Hba and Hbb have varied 
expression. Hba increases from 5 – 17 months old in 
rats [37] and decreases from 5 – 12 months old in mice 
[54]. There are currently limited mitochondrial papers 
profiling the subunits of Hb - perhaps in some cases this 
is due to relegating it to cytosolic status and subsequent 
removal from the published data. With decreased 
expression changes of Hba and Hbb in functional 
studies of ageing [141] and neurodegeneration 
[104,106,107], and agreement from mitochondrial 
proteomic profiling, it would be prudent for further 
studies to elucidate whether Hb expression changes are 
a cause or consequence of the process. 
 
Carbonic anhydrase II 
 
Carbonic anhydrases (CA) are a family of zinc 
metalloenzymes tasked with catalysis of the reversible 
hydration of carbon dioxide (CO2) to bicarbonate 
(HCO3-). Further they are involved in the exchange of 
carbon dioxide in tissues and the formation of bodily 
fluids, including aqueous humour, saliva, bile, urine, 
pancreatic juice, gastric secretion, sweat and 
cerebrospinal fluid [144]. In mammals there is the α 
family, consisting of at least 16 different CA isoforms, 
which differ by tissue location, subcellular localisation, 
catalytic activity (reviewed by Supuran, 2016) [144]. 
For such a ubiquitous family with wide ranging tasks 
there is a lack of knowledge as to the 
pathophysiological effect their dysfunction may have, 
not least within ageing. 
 
Carbonic anhydrase II (CAII) is a widely distributed 
isoform – present in the cytosol of a large number of 
cell and tissue types. It is the target of inhibitors for the 
treatment of glaucoma[145], cancer [145] and epilepsy 
[146]. Further, the CAII inhibitor methazolamide has 
recently been shown to be neuroprotective in a mouse 
model of Alzheimer’s disease [147]. Recent mito-
chondrial proteomic profiles of mouse brain at 5 – 12 
months old [54] and 4-11 to 78 weeks old [7] have 
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shown an increase in CAII levels. Increased CAII levels 
with age have also been identified in various other 
tissues, including mouse retina [7], rat muscle 
[148,149], kidney [150] and human muscle [151]. These 
data suggest CAII associates with strong affinity to the 
mitochondrial outer membrane. Recent work by our 
group has made some progress in understanding the role 
of CAII in ageing [7]. In the long-lived nematode, 
C.elegans, a reduction in lifespan was found with the 
addition of CAII. Increased CAII expression is not 
exclusively an ageing phenomenon. In the pcd 
neurodegenerative mouse model a significant increase 
in CAII was seen in brain cerebellum and retina [7]. 
Evidence points towards upregulation of CAII as an 
event of both ageing and neurodegeneration. It is likely 
that upregulation of CAII is a feature of other 
neurodegenerative diseases, not limited to glaucoma 
[145]. Increased expression of CAII from ageing brain 
mitochondrial proteomic profiles and lifespan reduction 
of C.elegans by addition of CAII clearly displays it as 
an exciting novel regulator of ageing that warrants 
further study to elicit its role in this process. The 
possibility of CAII upregulation in neurodegenerative 
diseases also requires investigation as currently in use 





Recent mitochondrial proteomic analyses of brain tissue 
from mice and rats has provided many more questions 
than answers to the already conflicting results from 
functional studies. It is clear that oxidative phosphoryla-
tion complexes and TCA cycle proteins are affected by 
age, however the directionality and extent to these 
changes is in question. Proteomic analyses of whole 
brain, neuronal compartments and specific cell types 
have highlighted the heterogeneity of mitochondrial 
protein expression changes with age. Looking at whole 
brain samples, the consensus from these proteomic 
studies is a decrease in expression of TCA cycle proteins 
and complexes I, IV and V, with some evidence for 
decreases in complexes II and III expression. Synaptic 
datasets suggest an opposing proteomic profile. Future 
work in this area will need to ensure an understanding of 
this potential for differential mitochondrial protein 
expression between regions and cell types.  
 
Age ranges used for profiling in these studies cover the 
lifespan, highlighting an important point that similar to 
findings from gene expression analyses, a dynamic time 
course for mitochondrial protein expression exists [61]. 
In whole brain OXPHOS complexes and TCA cycle this 
tends to be an upregulation from young to adult and a 
corresponding downregulation from adult to old. Whole 
lifespan changes seem to be minimal, perhaps reflecting 
a see-saw effect of protein expression changes with age. 
Special consideration should be taken when planning 
future experimental work in this area to consider these 
changes at different stages of life. Further work should 
focus upon elucidating the mitochondrial proteomic 
changes at smaller time intervals in order to define 'age 
boundaries' for future ageing-targeted therapies. 
 
A previously limited area of knowledge was 
mitochondrial HSP expression with age. This review 
has brought together the evidence, from proteomic 
profiling, that mitochondrial specific HSPs (HSP10, 60, 
70) are downregulated in old aged whole brain tissue. 
Previous age related functional and proteomic studies 
have found tissue specific expression patterns, with 
increased mtHSP70 in rat kidney and lungs, decrease in 
rat testis and no change in liver with ageing [100]. 
Another group found brain region specific differences 
in HSP60 levels with a loss in the substantia nigra and 
no change in the striatum [95]. Due to this loss in 
protein folding capability, age may create an 
environment more suitable for substantia nigra 
mitochondrial dysfunction, and thus the onset of 
Parkinson’s disease. Since there is agreement from the 
mitochondrial proteomic profiles that an overall 
reduction in mitochondrial HSP expression with old age 
exists, further study should address expression changes 
within specific brain regions and the impact decreased 
expression, and its alteration, may have on lifespan and 
neurodegenerative disease. 
 
Taken together, in whole brain there seems to be a 
mitochondrial proteomic movement toward decreased 
apoptosis with advanced age. Downregulation of 
OXPHOS complexes has been shown to reduce 
susceptibility to apoptosis [152]. Potentially pro-
apoptotic mitochondrial HSPs [83, 86] and VDACs 
[126] are seen to have decreased expression in the 
mitochondrial proteomic profiling here. Mitochondrial 
fission is an early event in apoptosis [153] and is a 
mediator of cytochrome C release [154]. With the 
decreased expression of mitochondrial fission proteins 
here, this would suggest an anti-apoptotic phenotype. 
An overarching question still posed is the direction of 
apoptosis with ageing. Analysis of mitochondrial 
proteomic profiles would suggest an anti-apoptotic 
phenotype in whole brain. 
 
Brain mitochondrial proteomic profiling has pulled out 
intriguing novel proteins modulated by age. Carbonic 
anhydrase II is one such protein, suggested to have 
strong affinity to the mitochondrial outer membrane. 
Two brain mitochondrial proteomic studies found an 
increase in CAII expression in young to adult mice [7, 
54], indicating a role in the regulation of ageing. 
Addition of CAII in C.elegans has corroborated its 
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importance by producing a decrease in lifespan [7]. 
CAII holds exciting possibilities as a novel regulator of 
ageing, however little understanding of its role is 
currently known. With CAII inhibitors in use for 
glaucoma [145], cancer [145] and epilepsy [146], an 
exciting possibility is its use to improve ageing 
outcomes.  
 
As proteomic technologies have improved a number of 
the more recent proteomic studies within this review 
have moved away from gel-based techniques. Using 
newer technologies a greater number of mitochondrial 
protein expression changes were seen. SILAC 
combined with LC/MS-MS boasts improved sensitivity 
for measurement of lower abundance proteins [40], 
however the cost and its inability to directly analyse 
tissues are drawbacks to its use [45]. The use of the 
older methodology 2DE still works for these 
mitochondrial proteomic profiles finding fewer protein 
expression differences, however the small size of the 
mitochondrial proteome makes it suitable for this use. 
Ageing and mitochondrial antioxidants, VDAC 
proteins, fusion and fission protein dynamics, 
haemoglobin subunits, heat shock proteins and carbonic 
anhydrases have varied, or limited, description in 
functional studies. As future technologies, including 
SWATH-MS [47], with the ability to measure at a 
greater resolution, reproducibility and higher sensitivity 
become more widespread we may be able to profile the 
lower abundance proteins involved in other 
mitochondrial functions: biogenesis [155], mitophagy 
[156] and steroid synthesis [157], which have been seen 
to have altered expression in functional studies. Overall 
mitochondrial proteomic research is already challenging 
our ideas of ageing and can be seen to be of great utility 




Mitochondrial proteomic alteration in brain ageing is 
clear, however the directionality and extent of these 
alterations is not. The application of quantitative 
proteomics to mitochondria is timely to more 
comprehensively investigate these changes. Mito-
chondrial proteomics of brain ageing has elucidated 
expression changes in key mitochondrial proteins over 
the lifespan and highlighted the heterogeneity that may 
occur between cell types and cell regions. The 
establishment of biological markers of ageing will allow 
for a more coherent theory of brain ageing, the 
development of diagnostic criteria to differentiate 
between ageing and age-related diseases and the 
validation of potential targets for the improvement and 
elongation of health and lifespan. With the advent of 
new proteomic technologies, bringing greater 
reproducibility and accuracy, the field of mitochondrial 
proteomics is open-ended and improved clarity of the 
mitochondrial changes that occur in the brain with age 
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